Sofosbuvir and Ribavirin Eradication of Refractory Hepatitis E in an Immunosuppressed Kidney Transplant Recipient
Mary Drinane, Xiao Jing Wang, Kymberly Watt – 14 December 2018
Mary Drinane, Xiao Jing Wang, Kymberly Watt – 14 December 2018
Baris D. Yildiz – 14 December 2018
Shuyun Rao, Lopa Mishra – 14 December 2018
Jérôme Dumortier, Sophie Dupuis‐Girod, Pierre‐Jean Valette, Alexander Valent, Olivier Guillaud, Jean‐Christophe Saurin, Valérie Hervieu, Philip Robinson, Henri Plauchu, Pierre Paliard, Olivier Boillot, Jean‐Yves Scoazec – 14 December 2018 – Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement. We provide a long‐term evaluation of graft status after LT for HHT, with a focus on the risk of recurrence.
Neil Mehta, Jennifer L. Dodge, John P. Roberts, Ryutaro Hirose, Francis Y. Yao – 13 December 2018 – High alpha‐fetoprotein (AFP) > 1,000 ng/mL is associated with poor outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC). A new national policy has been implemented for AFP > 1,000 ng/mL requiring a decrease to < 500 ng/mL before LT, but there is a paucity of data on the optimal AFP threshold before LT.
Li Chen, David A. Brenner, Tatiana Kisseleva – 13 December 2018 – Hepatic fibrosis results from chronic injury and inflammation in the liver and leads to cirrhosis, liver failure, and portal hypertension. Understanding the molecular mechanisms underlying hepatic fibrosis has advanced the prospect of developing therapies for regression of the disease.
Li Chen, David A. Brenner, Tatiana Kisseleva – 13 December 2018 – Hepatic fibrosis results from chronic injury and inflammation in the liver and leads to cirrhosis, liver failure, and portal hypertension. Understanding the molecular mechanisms underlying hepatic fibrosis has advanced the prospect of developing therapies for regression of the disease.
11 December 2018